2021 ASCO Virtual Annual Meeting*

In this exploratory analysis performed at a median follow-up of approximately 4.5 years, ribociclib + fulvestrant maintained OS benefit vs placebo + fulvestrant in postmenopausal patients with HR+/HER2- advanced breast cancer.

In subgroup analyses of the phase III ASCENT trial, sacituzumab govitecan maintained benefit and a consistent safety profile vs single-agent chemotherapy among patients aged ≥65 years, among those in the second-line setting with disease TNBC recurrence ≤12 months after (neo)adjuvant therapy, and when compared with individual chemotherapy agents.

In this analysis of survival outcomes at a median follow-up of approximately 3.5 years, the addition of durvalumab to neoadjuvant CT significantly prolonged iDFS, distant DFS, and OS vs placebo + neoadjuvant CT in patients with early TNBC.

In this prespecified subgroup analysis of patients with HR+/HER2- early breast cancer who received prior neoadjuvant chemotherapy, the subgroup showed a higher risk of recurrence vs the ITT population and had a numerically greater benefit for both invasive DFS and distant RFS with abemaciclib + adjuvant ET.

This phase III trial showed that pafolacianine sodium injection with intraoperative near-infrared fluorescence imaging detects additional lesions for surgical resection that would otherwise be missed by white light and palpation.

Adavosertib with or without olaparib demonstrated clinical activity with a manageable toxicity profile in patients with PARPi-resistant ovarian cancer, regardless of BRCA status.

In the randomized TOTEM trial, intensive follow-up did not improve overall survival, relapse-free survival, or health-related quality-of-life outcomes vs minimalist follow-up in patients treated for endometrial cancer.

Data from 3 phase III studies confirm efficacy of niraparib maintenance treatment in patients with BRCAm ovarian cancer following platinum-based chemotherapy in first-line and recurrent disease settings.

Niraparib plus dostarlimab yields a clinical benefit rate of 31.8% vs 20.0% with monotherapy in patients with recurrent EC enriched for platinum resistant disease.

In this prespecified interim analysis of patients with germline BRCA1/2-mutated, HER2-negative early breast cancer at high risk of recurrence, adjuvant olaparib for 1 year significantly improved invasive and distant disease–free survival vs placebo.

In women with locally advanced cervical cancer, use of adjuvant carboplatin/paclitaxel after standard cisplatin-based CRT did not improve OS or PFS at 5 years.